Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM LUMRY

NPI
1598715914
CMS profile
253219
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$253,902.38

304 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 7; records 201–250 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM LUMRY

NPI 1598715914 · CMS profile ID 253219

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598715914?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM LUMRY, NPI 1598715914, CMS profile ID 253219. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598715914?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). WILLIAM LUMRY, NPI 1598715914, CMS profile ID 253219. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598715914?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
WILLIAM LUMRY, NPI 1598715914, CMS profile ID 253219, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598715914?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

304 matching records · $253,902.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 304 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 304.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
OptiNose US, Inc. $586.5704/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256659 CMS
OptiNose US, Inc. $74.4304/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256661 CMS
Shire North American Group Inc $1,100.0004/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868989 CMS
Shire North American Group Inc $25.0004/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868983 CMS
Shire North American Group Inc $25.0004/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868985 CMS
Shire North American Group Inc $64.9504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868987 CMS
AstraZeneca Pharmaceuticals LP $4,650.0004/07/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685247951 CMS
OptiNose US, Inc. $2,500.0004/07/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256651 CMS
CSL Behring $91.1004/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840009 CMS
ALK-Abello, Inc $54.5804/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698052621 CMS
Allergan Inc. $600.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670747339 CMS
Allergan Inc. $250.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670747341 CMS
Shire North American Group Inc $37.7404/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868975 CMS
Shire North American Group Inc $19.4304/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868977 CMS
Shire North American Group Inc $16.0804/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868979 CMS
Shire North American Group Inc $2,073.0804/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868981 CMS
Shire North American Group Inc $7,975.0004/02/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868973 CMS
Teva Pharmaceuticals USA, Inc. $61.1804/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697878761 CMS
GlaxoSmithKline, LLC. $14.2804/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670277213 CMS
Shire North American Group Inc $751.3803/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868971 CMS
Shire North American Group Inc $50.0003/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868969 CMS
AstraZeneca Pharmaceuticals LP $49.5303/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685354875 CMS
AstraZeneca Pharmaceuticals LP $32.4903/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685360093 CMS
AstraZeneca Pharmaceuticals LP $23.2203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685761975 CMS
AstraZeneca Pharmaceuticals LP $79.2003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685770337 CMS
AstraZeneca Pharmaceuticals LP $23.2203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685810677 CMS
AstraZeneca Pharmaceuticals LP $266.4803/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685886371 CMS
AstraZeneca Pharmaceuticals LP $73.1903/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685905317 CMS
AstraZeneca Pharmaceuticals LP $200.0003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685953361 CMS
Genentech USA, Inc. $2,625.0003/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681311663 CMS
Genentech USA, Inc. $11.6003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681313385 CMS
AstraZeneca Pharmaceuticals LP $1,850.0003/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685151105 CMS
GlaxoSmithKline, LLC. $13.5303/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671435867 CMS
Shire North American Group Inc $2,750.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868957 CMS
Shire North American Group Inc $12.7903/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868959 CMS
Shire North American Group Inc $51.0003/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868961 CMS
Shire North American Group Inc $38.0103/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868963 CMS
Shire North American Group Inc $113.9603/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868965 CMS
Shire North American Group Inc $5,087.5003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637868967 CMS
OptiNose US, Inc. $163.1903/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256615 CMS
OptiNose US, Inc. $40.0003/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256617 CMS
OptiNose US, Inc. $45.9103/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256619 CMS
OptiNose US, Inc. $51.7303/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256621 CMS
OptiNose US, Inc. $34.5703/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684256623 CMS
AstraZeneca Pharmaceuticals LP $14.6303/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685978617 CMS
AstraZeneca Pharmaceuticals LP $9.6503/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685147011 CMS
AstraZeneca Pharmaceuticals LP $19.7203/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685708453 CMS
AstraZeneca Pharmaceuticals LP $124.9903/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685987315 CMS
CSL Behring $124.4603/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683839997 CMS
CSL Behring $4,718.0003/12/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683839999 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $253,902.38 304
PY2020 $68,706.84 89
PY2021 $137,516.11 171
PY2022 $197,481.97 233
PY2023 $234,781.76 285
PY2024 $241,895.22 234
PY2025 $202,615.40 191

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $12,207.00 9
PY2025 Principal investigator $49,568.97 14
PY2024 Recipient $33,091.03 14
PY2024 Principal investigator $37,773.89 8
PY2023 Recipient $6,788.29 8
PY2023 Principal investigator $29,119.22 25
PY2022 Recipient $76,478.92 6
PY2022 Principal investigator $99,149.32 49
PY2021 Recipient $97,177.55 8
PY2021 Principal investigator $831,761.05 68
PY2020 Recipient $20,281.80 6
PY2020 Principal investigator $337,424.41 57
PY2019 Recipient $81,948.93 10
PY2019 Principal investigator $627,546.99 100

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient CSL Behring $676.00 12/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664847
Principal investigator 1 Ionis Pharmaceuticals, Inc. $7,142.47 12/12/2025 Non-covered Recipient Entity
WILLIAM R LUMRY MD PA
IS744CS7 No dispute reported 06/30/2026 1246791525
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,020.00 11/25/2025 Non-covered Recipient Entity
AARA RESEARCH CENTER
Ionis Pharmaceuticals, Inc.ISIS 721744--EO1 No dispute reported 06/30/2026 1246790764
Recipient CSL Behring $1,661.00 11/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664845
Recipient CSL Behring $2,646.00 10/22/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664843
Principal investigator 1 CSL Behring $58.00 10/02/2025 Non-covered Recipient Entity
Aara Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671758
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,954.75 09/24/2025 Non-covered Recipient Entity
WILLIAM R. LUMRY
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185548709
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 09/18/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046276
Principal investigator 1 CSL Behring $58.00 08/21/2025 Non-covered Recipient Entity
Aara Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671756
Principal investigator 1 Ionis Pharmaceuticals, Inc. $7,813.93 08/08/2025 Non-covered Recipient Entity
WILLIAM R LUMRY MD PA
IS744CS7 No dispute reported 06/30/2026 1246786370
Principal investigator 1 CSL Behring $231.78 07/14/2025 Non-covered Recipient Entity
Aara Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671754
Principal investigator 1 Eli Lilly and Company $20,235.96 06/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187878655
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,218.92 04/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046288
Recipient CSL Behring $1,424.00 03/14/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664841
Principal investigator 1 Novartis Pharmaceuticals Corporation $214.96 03/10/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY RESEARCH ASSOCIATION ASTHMA AND ALLERGY
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190312611
Recipient CSL Behring $500.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664833
Recipient CSL Behring $1,000.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664835
Recipient CSL Behring $1,500.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664837
Recipient CSL Behring $1,800.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664839
Recipient CSL Behring $1,000.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664849
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046062
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 02/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046034
Principal investigator 1 CSL Behring $347.40 01/15/2025 Non-covered Recipient Entity
Aara Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671752

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $2,000.00 1
PY2025 Value of interest $2,000.00 1
PY2024 Amount invested $2,000.00 1
PY2024 Value of interest $2,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Consortium of Independent Immunology Clinics, LLC $2,000.00 $2,000.00 n/a Physician Covered Recipient No dispute reported 06/30/2026 1228219927
PY2024 Consortium of Independent Immunology Clinics, LLC $2,000.00 $2,000.00 n/a Physician Covered Recipient No dispute reported 06/30/2026 1147269098